NVO (Novo Nordisk AS) Cyclically Adjusted Revenue per Share: $6.78 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NVO Novo Nordisk AS NVO
76 GF Score
Price $49.61
GF Value $135.84
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS Cyclically Adjusted Revenue per Share?

Novo Nordisk AS NVO -1.41% 76 Cyclically Adjusted Revenue per Share is $6.78 as of Mar. 2026. GuruFocus rates NVO with a GF Score™ of 76/100 and a GF Value™ of $135.84 (Significantly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Novo Nordisk AS's adjusted revenue per share for the three months ended in Mar. 2026 was $3.366. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $6.78 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Novo Nordisk AS's average Cyclically Adjusted Revenue Growth Rate was 14.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 14.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 15.10% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 12.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Novo Nordisk AS was 16.10% per year. The lowest was 6.30% per year. And the median was 12.40% per year.

As of today (2026-07-21), Novo Nordisk AS's current stock price is $49.61. Novo Nordisk AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $6.78. Novo Nordisk AS's Cyclically Adjusted PS Ratio of today is 7.32.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Novo Nordisk AS was 31.25. The lowest was 5.56. And the median was 10.95.


Novo Nordisk AS  (NYSE:NVO) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Novo Nordisk AS's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=49.61/6.78
=7.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Novo Nordisk AS was 31.25. The lowest was 5.56. And the median was 10.95.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Novo Nordisk AS Cyclically Adjusted Revenue per Share Related Terms


Novo Nordisk AS Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Novo Nordisk AS's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Nordisk AS Cyclically Adjusted Revenue per Share Chart

Novo Nordisk AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.49 3.93 4.55 4.93 6.40

Novo Nordisk AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.52 6.07 6.44 6.40 6.78

NVO vs LLY, JNJ, ABBV: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk AS Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's Cyclically Adjusted PS Ratio falls into.


NVO
76GF Score
Novo Nordisk AS NVO
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novo Nordisk AS Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novo Nordisk AS's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=3.366/121.6800*121.6800
=3.366

Current CPI (Mar. 2026) = 121.6800.

Novo Nordisk AS Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.816 100.600 0.987
201609 0.819 100.200 0.995
201612 0.833 100.300 1.011
201703 0.818 101.200 0.984
201706 0.881 101.200 1.059
201709 0.863 101.800 1.032
201712 0.904 101.300 1.086
201803 0.913 101.700 1.092
201806 0.884 102.300 1.051
201809 0.897 102.400 1.066
201812 0.942 102.100 1.123
201903 0.927 102.900 1.096
201906 0.953 102.900 1.127
201909 0.941 102.900 1.113
201912 1.020 102.900 1.206
202003 1.063 103.300 1.252
202006 0.966 103.200 1.139
202009 1.049 103.500 1.233
202012 1.130 103.400 1.330
202103 1.168 104.300 1.363
202106 1.160 105.000 1.344
202109 1.227 105.800 1.411
202112 1.270 106.600 1.450
202203 1.363 109.900 1.509
202206 1.288 113.600 1.380
202209 1.336 116.400 1.397
202212 1.514 115.900 1.590
202303 1.701 117.300 1.765
202306 1.755 116.400 1.835
202309 1.872 117.400 1.940
202312 2.154 116.700 2.246
202403 2.131 118.400 2.190
202406 2.198 118.500 2.257
202409 2.380 118.900 2.436
202412 2.700 118.900 2.763
202503 2.545 120.200 2.576
202506 2.672 120.700 2.694
202509 2.651 121.600 2.653
202512 2.789 121.200 2.800
202603 3.366 121.680 3.366

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $6.78 mean?
Novo Nordisk AS (NVO) has a Cyclically Adjusted Revenue per Share of $6.78 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Novo Nordisk AS and its competitors.
Is Novo Nordisk AS's Cyclically Adjusted Revenue per Share too high?
Novo Nordisk AS's current Cyclically Adjusted Revenue per Share is $6.78. Overall, Novo Nordisk AS has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Cyclically Adjusted Revenue per Share compare to LLY and JNJ?
Novo Nordisk AS's Cyclically Adjusted Revenue per Share of $6.78 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Novo Nordisk AS and its competitors. Novo Nordisk AS's current Cyclically Adjusted Revenue per Share is $6.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (NVO) is currently considered Significantly Undervalued. The stock's GF Value™ is $135.84, compared to a current price of $49.61 — trading 63.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $6.78. Novo Nordisk AS's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Novo Nordisk AS (NVO), the current Cyclically Adjusted Revenue per Share is $6.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novo Nordisk AS (NVO) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of $49.61 is trading 63.5% below its estimated GF Value™ of $135.84. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for NVO:

  • Cyclically Adjusted Revenue per Share: $6.78
  • GF Value™: $135.84 vs. price of $49.61 (63.5% below fair value)
  • GF Score™: 76/100 with 4 warning signs

No single metric tells the full story. See the NVO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
76GF Score

Get the complete analysis for NVO

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$49.61
Price
$135.84
GF Value